Mackenzie Financial Corp Has $33.86 Million Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Mackenzie Financial Corp raised its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,169,176 shares of the company's stock after purchasing an additional 238,335 shares during the period. Mackenzie Financial Corp owned 2.06% of Maravai LifeSciences worth $33,858,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Captrust Financial Advisors increased its position in Maravai LifeSciences by 1.3% during the first quarter. Captrust Financial Advisors now owns 33,535 shares of the company's stock worth $1,183,000 after purchasing an additional 442 shares during the last quarter. Zions Bancorporation N.A. bought a new position in Maravai LifeSciences during the 1st quarter valued at $28,000. Public Employees Retirement System of Ohio boosted its stake in Maravai LifeSciences by 2.1% during the 4th quarter. Public Employees Retirement System of Ohio now owns 56,289 shares of the company's stock valued at $805,000 after acquiring an additional 1,181 shares during the last quarter. Comerica Bank bought a new position in Maravai LifeSciences during the 2nd quarter valued at $180,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Maravai LifeSciences by 96.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company's stock valued at $34,000 after acquiring an additional 1,662 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analysts Set New Price Targets

MRVI has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on shares of Maravai LifeSciences in a research note on Wednesday, April 10th. They set a "buy" rating and a $15.00 price objective on the stock. Stifel Nicolaus reduced their price objective on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, February 23rd. Finally, Royal Bank of Canada raised their price target on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Maravai LifeSciences currently has a consensus rating of "Moderate Buy" and an average target price of $11.56.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock traded down $0.12 during trading hours on Thursday, hitting $7.61. 1,628,418 shares of the company traded hands, compared to its average volume of 2,627,160. The firm has a market cap of $1.91 billion, a P/E ratio of -8.47 and a beta of 0.01. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The firm's 50-day simple moving average is $7.48 and its two-hundred day simple moving average is $6.76. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.52 and a 1-year high of $16.62.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. The company had revenue of $74.14 million for the quarter, compared to analysts' expectations of $62.99 million. As a group, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.